Endocrine Abstracts

Objective: Vitamin D has potential immunomodulatory effects. We studied whether vitamin D3 supplementation affects the course of Graves’ disease (GD).Methods: In a double-blind, placebo-controlled design, we randomized patients with a first time diagnosis of GD hyperthyroidism to daily supplementation with vitamin D3 70 mg (2800 IU) or placebo, as add-on to standard treatment with anti-thyroid drugs (ATD). The intervention was continued 12 months af...

Background: Vitamin D is important to skeletal health and is standard care in conditions with low BMD. Thyrotoxicosis caused by Graves’ disease (GD) leads to increased bone turnover and reduced BMD. We aimed to test the hypothesis that vitamin D supplementation would improve bone recovery in GD.Methods: Using a double-blinded design, hyperthyroid patients with a first time diagnosis of GD were randomized to supplementation with vitamin D3 70 mg/day...

Background: Vitamin D deficiency has been proposed to play a role in development and course of Graves’ disease (GD). Muscle weakness and fatigue are shared features of GD and vitamin D deficiency. We aimed to investigate whether vitamin D supplementation would improve restoration of muscle performance and thyroid-related quality of life (QoL) in GD.Methods: In a double-blinded clinical trial, hyperthyroid patients with a first time diagnosis of GD w...

Background: Risk of cardiovascular disease (CVD) and mortality is increased in Graves’ disease (GD) even years after initial diagnosis and treatment. The mechanisms are incompletely understood. Vitamin D insufficiency is associated with an increased risk of CVD and has been reported to occur frequently in GD. Pulse wave velocity (PWV) and blood pressure (BP) are important predictors of CVD. We performed a clinical trial, testing whether vitamin D supplementation affects P...

Objectives: Quality of life (QoL) is severely affected in Graves’ disease (GD) but long-term longitudinal assessment of QoL is lacking. Furthermore, whether QoL is comparable to controls after treatment of GD is unclear. For the first time, we present serial, longitudinal data on thyroid-related QoL during 24 months of follow-up in a cohort of newly diagnosed GD patients. In addition, we compare QoL in GD and controls.Methods: All patients were tre...